Clinical response to MEL100 and MP
. | MEL 100, no. (%) . | MP, no. (%) . | P . |
|---|---|---|---|
| No. | 95 (100) | 99 (100) | NA |
| Near complete remission | 24 (25) | 6 (6) | .0002 |
| Partial remission | |||
| 75% to 99% reduction | 24 (25) | 11 (11) | <.0001 |
| 50% to 74% reduction | 21 (22) | 25 (25) | — |
| No response | 21 (22) | 35 (35) | — |
| Progressive disease | 4 (4) | 20 (20) | — |
| Not available | 1 (1) | 2 (2) | — |
| Early deaths | 5 (5) | 1 (1) | .6 |
. | MEL 100, no. (%) . | MP, no. (%) . | P . |
|---|---|---|---|
| No. | 95 (100) | 99 (100) | NA |
| Near complete remission | 24 (25) | 6 (6) | .0002 |
| Partial remission | |||
| 75% to 99% reduction | 24 (25) | 11 (11) | <.0001 |
| 50% to 74% reduction | 21 (22) | 25 (25) | — |
| No response | 21 (22) | 35 (35) | — |
| Progressive disease | 4 (4) | 20 (20) | — |
| Not available | 1 (1) | 2 (2) | — |
| Early deaths | 5 (5) | 1 (1) | .6 |
NA indicates not applicable; —, not available.